Monitor for actual sales in upcoming days; given this is an officer selling recently vested equity and recent insider selling totals $2.6M in 30 days, consider this a bearish signal ahead of potential earnings or clinical updates. Pair with upcoming trading volume for confirmation of execution.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $18.84entry
- T+1 · 8mo ago −2.60%α −3.08% · $18.35
- T+5 · 7mo ago −0.85%α −4.47% · $18.68
- T+20 · 7mo ago −6.85%α −16.72% · $17.55
- T+60 · 5mo ago +17.89%α +3.73% · $22.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lucera Erick, an officer of Dyne Therapeutics, filed a Form 144 to notify intent to sell up to 57,270 shares of common stock, with an approximate value of $1.65 million based on recent market prices. The shares are from restricted stock units and equity compensation, and the filing was submitted by Stifel Nicolaus & Company Inc as attorney-in-fact.
Key Facts
- Reporting owner: Lucera Erick, officer of Dyne Therapeutics
- Shares proposed for sale: 57,270
- Approximate dollar value: $1,650,271 (based on $28.81/share)
- Shares acquired via: Restricted Stock Units and equity compensation
- Acquisition date: March 31, 2026
- Filing date: April 1, 2026
- Broker: Stifel Nicolaus & Company Inc, acting as attorney-in-fact
Financial Impact
$1.65 million in insider selling intent, representing full liquidation of recently vested RSUs
Risk Factors
- Insider selling may accelerate if near-term catalysts disappoint
- Lack of offsetting insider buying increases perception of weak confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001972481-26-000124 |
| Document: 0001972481-26-000124-index.html | 0001972481-26-000124 |
| Document: 0001972481-26-000124.txt | 0001972481-26-000124 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers